UTILITY

PATENT APPLICATION

Which was not published in English

☐ This application claims priority of provisional application Serial No.

Attorney Docket No.	216432US0X DIV

First Inventor or Application Identifier Kokichi KIK

APABLE OF INDUCING IN THE RESPONSE TO HUMAN ANCER AND AGENT FOR PREVENTING OR TREATING PEPTIDE CAPABLE OF INDUCING HUMAN GASTRIC CANCER, CONTAINING THE PEPTIDE

1. AJINOMOTO CO., INC.

Kokichi Kikuchi

Filed

Assianee Address

Title

1. 15-1. Kyobashi 1-chome, Chuo-ku, Tokyo, JAPAN

2. 7-1, Fushimi 3-chome, Chuo-ku, Sapporo-shi, Hokkaido, JAPAI

Assistant Commissioner for Patents APPLICATION ELEMENTS Box Patent Application Washington, DC 20231 ADDRESS TO: See MPEP chapter t-00 concerning utility patent application contents Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing) **ACCOMPANYING APPLICATION PARTS** 7 Assignment Papers (cover sheet & document(s)) Application Data Sheet. See 37 CFR 1.76 Specification Total Sheets 33 37 C.F.R. §3.73(b) Statement (when there is an assignee) □ Power of Attorney 9 Formal Drawing(s) (35 U.S.C. 113) ☐ English Translation Document (if applicable) 4 10 **Total Sheets** Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations 11 Total Pages Oath or Declaration 12 Preliminary Amendment a.

 □ Newly executed (original or copy) 13 White Advance Serial No. Postcard Copy from a prior application (37 C.F.R, §1.63(d)) (for continuation / divisional w/ box 17 completed) Certified Copy of Priority Document(s) (if foreign priority is claimed) DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the pricr application see 37 C.F.R. §1.63(d)(2) and Applicant claims small entity status. See 37 CFR 1.27 CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 5 Request for Priority Other: Nucleotide and/or Amino Acid Sequence Submission 6 (if applicable, all necessary) a.

 □ Computer Readable Form (CRF) b. Specification or Sequence Listing on: i.

CD-ROM or CD-R (2 copies); or Paper c.

Statements verifying identity of above copies If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below: □ Continuation-in-part (CIP) of prior application no.: 09/103,808 Continuation Divisional Group Art Unit: 1633 Prior application information: Examiner: S. Kaushal For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 18. Amend the specification by inserting before the first line the sentence: ■ This application is a □ Continuation Division □ Continuation-in-part (CIP) June 24, 1998, allowed, which is a divisional of application Serial No. 08/723,116, filed on September 30, 1996, now U.S. Patent 09/103,808 of application Serial No. Filed on Which was published in English

19. CORRESPONDENCE ADDRESS



22850

(703) 413-3000 FACSIMILE: (703) 413-2220

Name:	Norman F. Oblon	Registration No.	24,618
Signature:	Seft Bell	Date	Jan 8 2002
Name:	Stephen G. Bakter, Ph.D.	Registration No	32,884

IN RE APPLICATION OF: Kokichi KIKUCHI, et al.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GAU:

SERIAL NO: New Application

EXAMINER:

FILED:

Herewith

FOR:

PEPTIDE CAPABLE OF INDUCING IMMUNE RESPONSE TO HUMAN GASTRIC CANCER AND AGENT

FOR PREVENTING OR TREATING HUMAN GASTRIC CANCER, CONTAINING THE PEPTIDE

REQUEST FOR PRIORITY

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

- Full benefit of the filing date of U.S. Application Serial Number 09/103,808, filed June 24, 1998 and U.S. Application Serial Number 08/723,116, filed September 30, 1996, is claimed pursuant to the provisions of 35 U.S.C. §120.
- □ Full benefit of the filing date of U.S. Provisional Application Serial Number, filed, is claimed pursuant to the provisions of 35 U.S.C. §119(e).
- Applicants claim any right to priority from any earlier filed applications to which they may be entitled pursuant to the provisions of 35 U.S.C. §119, as noted below.

In the matter of the above-identified application for patent, notice is hereby given that the applicants claim as priority:

COUNTRY	APPLICATION NUMBER	MONTH/DAY/YEAR
JAPAN	7-253491	09/29/95
JAPAN	8-217140	08/19/96

Certified copies of the corresponding Convention Application(s)

- are submitted herewith
- □ will be submitted prior to payment of the Final Fee
- were filed in prior application Serial No. 08/723,116 filed September 30, 1996.
- were submitted to the International Bureau in PCT Application Number
 Receipt of the certified copies by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.
- ☐ (A) Application Serial No.(s) were filed in prior application Serial No. filed ; and
 - (B) Application Serial No.(s)
 - □ are submitted herewith
 - □ will be submitted prior to payment of the Final Fee

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,

MAJER & NEUSTADI P.C

Vørman F. Oblon

Registration No. 24,618

Stephen G. Baxter, Ph.D. Registration No. 32,884

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/98) Docket No.

216432US0X DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) Kokichi KIKUCIII, et al.

SERIAL NO:

New Application

FILING DATE: Herewith

FOR:

PEPTIDE CAPABLE OF INDUCING IMMUNE RESPONSE TO HUMAN GASTRIC CANCER AND

AGENT FOR PREVENTING OR TREATING HUMAN GASTRIC CANCER, CONTAINING THE PEPTIDE

FEE TRANSMITTAL

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	7 - 20 =	0	× \$18 -	\$0.00
INDEPENDENT CLAIMS	4 - 3 =	1	× \$84 =	\$84.00
□ MULTIPLE DEPENDENT CLAIMS (If applicable) + \$280 =			\$0.00	
☐ LATE FILING OF DECLARATION + \$130 =			\$0.00	
	\$740.00			
TOTAL OF ABOVE CALCULATIONS			\$824.00	
□ REDUCTION BY 50% FOR FILING BY SMALL ENTITY				\$0.00
□ FILING IN NON-ENGLISH LANGUAGE		+ \$130 =	\$0.00	
□ RECORDATION OF AS	SIGNMENT		+ \$4() =	\$0.00
			TOTAL	\$824.00

Please charge Deposit Account No. 15-0030 in the amount of

A duplicate copy of this sheet is enclosed.

A check in the amount of

\$824.00

to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully Submitted.

OBLON, SPIVAK, McCLELLAND,

MAIEB & NEUSTADT, P.C.

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10:00)

Norman F. Oblon

Registration No. 24,618

Stephen G. Baxter, Ph.D.

Registration No. 32,884